ES2569528T3 - 4-pirazolil-N-arilpirimidin-2-aminas y 4-pirazolil-N-heteroarilpirimidin-2-aminas como inhibidores de quinasas Janus - Google Patents

4-pirazolil-N-arilpirimidin-2-aminas y 4-pirazolil-N-heteroarilpirimidin-2-aminas como inhibidores de quinasas Janus Download PDF

Info

Publication number
ES2569528T3
ES2569528T3 ES08848610.5T ES08848610T ES2569528T3 ES 2569528 T3 ES2569528 T3 ES 2569528T3 ES 08848610 T ES08848610 T ES 08848610T ES 2569528 T3 ES2569528 T3 ES 2569528T3
Authority
ES
Spain
Prior art keywords
pyrazol
pyrimidin
phenylamino
carbonyl
ylamino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES08848610.5T
Other languages
English (en)
Inventor
Yun-Long Li
Wenqing Yao
James D. Rodgers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Incyte Holdings Corp
Original Assignee
Incyte Holdings Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40380038&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2569528(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Incyte Holdings Corp filed Critical Incyte Holdings Corp
Application granted granted Critical
Publication of ES2569528T3 publication Critical patent/ES2569528T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)

Abstract

Un compuesto de Fórmula IIa, IIb, IIc, IId, IIe, IIf o IIg:**Fórmula** o sal farmacéuticamente aceptable del mismo, en el que: El anillo A es arilo o heteroarilo; Q es H, Cy1, halo, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, haloalquilo C1-6, CN, NO2, ORa1, SRa1, C(O)Rb1, C(O)NRc1Rd1, C(O)ORa1, OC(O)Rb1, OC(O)NRc1Rd1, NRc1Rd1, NRc1C(O)Rb1, NRc1C(O)NRc1Rd1, NRc1C(O)ORa1, C(>=NRg)NRc1Rd1, NRc1C(>=NRg)NRc1Rd1, S(O)Rb1, S(O)NRc1Rd1, S(O)2Rb1, NRc1S(O)2Rb1, o S(O)2NRc1Rd1, en donde dichos alquilo C1-6, alquenilo C2-6 o alquinilo C2-6, están opcionalmente sustituidos con 1, 2, 3, 4 ó 5 sustituyentes seleccionados independientemente de halo, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, haloalquilo C1-6, halosulfanilo, CN, NO2, ORa1, SRa1, C(O)Rb1, C(O)NRc1Rd1, C(O)ORa1, OC(O)Rb1, OC(O)NRc1Rd1, NRc1Rd1, NRc1C(O)Rb1, NRc1C(O)NRc1Rd1, NRc1C(O)ORa1, C(>=NRg)NRc1Ra1, NRc1C(>=NRg)NRc1Ra1, S(O)Rb1, S(O)NRc1Rd1, S(O)2Rb1, NRc1S(O)2Rb1 y S(O)2NRc1Rd1; X es halo, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, haloalquilo C1-6, CN, NO2, ORa, SRa, C(O)Rb, C(O)NRcRd, C(O)ORa, OC(O)Rb, OC(O)NRcRd, NRcRd, NRcC(O)Rb, NRcC(O)NRcRd, NRcC(O)ORa, C(>=NRg)NRcRd, NRcC(>=NRg)NRcRd, S(O)Rb, S(O)NRcRd, S(O)2Rb, NRcS(O)2Rb, o S(O)2NRcRd, Y es H, Cy2, halo, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, haloalquilo C1-6, CN, NO2, ORa1, SRa1, C(O)Rb1, C(O)NRc1Rd1, C(O)ORa1, OC(O)Rb1, OC(O)NRc1Rd1, NRc1Rd1, NRc1C(O)Rb1, NRc1C(O)NRc1Rd1, NRc1C(O)ORa1, C(>=NRg)NRc1Rd1, NRc1C(>=NRg)NRc1Rd1, S(O)Rb1, S(O)NRc1Rd1, S(O)2Rb1, NRc1S(O)2Rb1, o S(O)2NRc1Rd1, en donde dichos alquilo C1-6, alquenilo C2-6, alquinilo C2-6 o haloalquilo C1-6 están opcionalmente sustituidos con 1, 2, 3, 4 ó 5 sustituyentes seleccionados independientemente de halo, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, haloalquilo C1-6, halosulfanilo, CN, NO2, ORa1, SRa1, C(O)Rb1, C(O)NRc1Rd1, C(O)ORa1, OC(O)Rb1, OC(O)NRc1Rd1, NRc1Rd1, NRc1C(O)Rb1, NRc1C(O)NRc1Rd1, NRc1C(O)ORa1, C(>=NRg)NRc1Ra1, NRc1C(>=NRg)NRc1Ra1, S(O)Rb1, S(O)NRc1Rd1, S(O)2Rb1, NRc1S(O)2Rb1 y S(O)2NRc1Rd1; R1, R2, R3 y R4 se seleccionan independientemente de H, halo, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, haloalquilo C1-6, CN, (CH2)mCN, NO2, ORa, (CH2)mORa, SRa, C(O)Rb, C(O)NRcRd, C(O)ORa, NRcRd, (CH2)mNRcRd, NRcC(O)Rb, NRcS(O)2Rb, y S(O)2NRcRd; Cy1 y Cy2 son seleccionados independientemente de arilo, cicloalquilo, heteroarilo y heterocicloalquilo, cada uno opcionalmente sustituido por 1, 2, 3, 4 ó 5 sustituyentes seleccionados independientemente de halo, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, arilo, cicloalquilo, heteroarilo, heterocicloalquilo, haloalquilo C1-6, halosulfanilo, CN, NO2, ORa1, SRa1, C(O)Rb1, C(O)NRc1Rd1, C(O)ORa1, OC(O)Rb1, OC(O)NRc1Rd1, NRc1Rd1, NRc1C(O)Rb1, NRc1C(O)NRc1Rd1, NRc1C(O)ORa1, C(>=NRg)NRc1Rd1, NRc1C(>=NRg)NRc1Ra1, S(O)Rb1, S(O)NRc1Rd1, S(O)2Rb1, NRc1S(O)2Rb1 y S(O)2NRc1Rd1, en donde dichos alquilo C1-6, alquenilo C2-6, alquinilo C2-6, arilo, cicloalquilo, heteroarilo o heterocicloalquilo que está sustituido en Cy1 o Cy2 está además opcionalmente sustituido por 1, 2 ó 3 sustituyentes seleccionados independientemente de halo, haloalquilo C1-6, halosulfanilo, CN, NO2, ORa1, SRa1, C(O)Rb1, C(O)NRc1Rd1, C(O)ORa1, OC(O)Rb1, OC(O)NRc1Rd1, NRc1Rd1, NRc1C(O)Rb1, NRc1C(O)NRc1Rd1, NRc1C(O)ORa1, C(>=NRg)NRc1Rd1, NRc1C(>=NRg)NRc1Ra1, S(O)Rb1, S(O)NRc1Rd1, S(O)2Rb1, NRc1S(O)2Rb1 y S(O)2NRc1Rd1; Ra, Rb, Rc y Rd se seleccionan independientemente de H, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, arilo, cicloalquilo, heteroarilo, heterocicloalquilo, arilalquilo, heteroarilalquilo, cicloalquilalquilo y heterocicloalquilalquilo, en donde dicho alquilo C1-6, alquenilo C2-6, alquinilo C2-6, arilo, cicloalquilo, heteroarilo, heterocicloalquilo, arilalquilo, heteroarilalquilo, cicloalquilalquilo o heterocicloalquilalquilo está opcionalmente sustituido con 1, 2, 3, 4 ó 5 sustituyentes seleccionados independientemente de OH, CN, amino, halo, alquilo C1-6, alcoxi C1-6, haloalquilo C1-6 y haloalcoxi C1-6. o Rc y Rd junto al átomo de N al que están unidos forman un grupo heterocicloalquilo o heteroarilo de 4-, 5-, 6- o 7- miembros, cada uno opcionalmente sustituido con 1, 2 ó 3 sustituyentes seleccionados independientemente de OH, CN, amino, halo, alquilo C1-6, alcoxi C1-6, haloalquilo C1-6 y haloalcoxi C1-6. Ra1, Rb1 Rc1 y Rd1 se seleccionan independientemente de H, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, arilo, cicloalquilo, heteroarilo, heterocicloalquilo, arilalquilo, heteroarilalquilo, cicloalquilalquilo y heterocicloalquilalquilo, en donde dicho alquilo C1-6, alquenilo C2-6, alquinilo C2-6, arilo, cicloalquilo, heteroarilo, heterocicloalquilo, arilalquilo, heteroarilalquilo, cicloalquilalquilo o heterocicloalquilalquilo está opcionalmente sustituido con 1, 2, 3, 4 ó 5 sustituyentes seleccionados independientemente de alquilo C1-6, halo, CN, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRc2C(O)NRc2Rd2, NRc2C(O)ORa2, C(>=NRg)NRc2Rd2, NRc2C(>=NRg)NRc2Rd2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, NRc2S(O)2Rb2 y S(O)2NRc2Rd2; o Rc1 y Rd1 junto al átomo de N al que están unidos forman un grupo heterocicloalquilo o heteroarilo de 4-, 5-, 6- o 7- miembros, cada uno opcionalmente sustituido con 1, 2 ó 3 sustituyentes seleccionados independientemente de alquilo C1-6, halo, CN, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRc2C(O)NRc2Rd2, NRc2C(O)ORa2, C(>=NRg)NRc2Rd2, NRc2C(>=NRg)NRc2Rd2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, NRc2S(O)2Rb2 y S(O)2NRc2Rd2; Ra2, Rb2 Rc2 y Rd2 se seleccionan independientemente de H, alquilo C1-6, haloalquilo C1-6, alquenilo C2-6, alquinilo C2-6, arilo, cicloalquilo, heteroarilo, heterocicloalquilo, arilalquilo, heteroarilalquilo, cicloalquilalquilo y heterocicloalquilalquilo, en donde dicho alquilo C1-6, haloalquilo C1-6, alquenilo C2-6, alquinilo C2-6, arilo, cicloalquilo, heteroarilo, heterocicloalquilo, arilalquilo, heteroarilalquilo, cicloalquilalquilo o heterocicloalquilalquilo está opcionalmente sustituido con 1, 2 ó 3 sustituyentes seleccionados independientemente de OH, CN, amino, halo, alquilo C1-6, alcoxi C1-6, haloalquilo C1-6 y haloalcoxi C1-6; o Rc2 y Rd2 junto al átomo de N al que están unidos forman un grupo heterocicloalquilo o heteroarilo de 4-, 5-, 6- o 7- miembros, cada uno opcionalmente sustituido con 1, 2 ó 3 sustituyentes seleccionados independientemente de OH, CN, amino, halo, alquilo C1-6, alcoxi C1-6, haloalquilo C1-6 y haloalcoxi C1-6; Rg es H, CN o NO2; y m es 0, 1, 2 ó 3.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14
imagen15
imagen16
imagen17
imagen18
imagen19
imagen20
imagen21
imagen22
imagen23
imagen24
imagen25
imagen26
imagen27
imagen28
imagen29
imagen30
imagen31
imagen32
imagen33
imagen34
imagen35
imagen36
imagen37
imagen38
imagen39
imagen40
imagen41
imagen42
imagen43
imagen44
imagen45
imagen46
imagen47
imagen48
imagen49
imagen50
imagen51
imagen52
imagen53
imagen54
imagen55
imagen56
imagen57
imagen58
imagen59
imagen60
imagen61
imagen62
imagen63
imagen64
imagen65
imagen66
imagen67
imagen68
imagen69
imagen70
imagen71
imagen72
imagen73
imagen74
imagen75
imagen76
imagen77
imagen78
imagen79
imagen80
imagen81
imagen82
imagen83
imagen84
imagen85
imagen86
imagen87
imagen88
imagen89
imagen90
imagen91
imagen92
imagen93
imagen94
imagen95
imagen96
imagen97
imagen98
imagen99
imagen100
imagen101
imagen102
imagen103
imagen104
imagen105
imagen106
imagen107
imagen108
imagen109
imagen110
imagen111
imagen112
imagen113
imagen114
imagen115
imagen116
imagen117
imagen118
imagen119
imagen120
imagen121
imagen122
imagen123
imagen124
imagen125
imagen126
imagen127
imagen128

Claims (1)

  1. imagen1
    imagen2
    imagen3
    imagen4
    imagen5
    imagen6
    imagen7
    (ciclopropilmetilamino)acetamida; N-(4-(4-(1-(2-ciano-1-ciclopentiletil)-1H-pirazol-4-il)pirimidin-2-ilamino)fenil)-2-(1-metoxipropan-2ilamino)acetamida; 3-ciclopentil-3-(4-(2-(4-(morfolin-4-carbonil)fenilamino)pirimidin-4-il)-1H-pirazol-1-il)propanonitrilo; 4-(4-(1-(2-ciano-1-ciclopentiletil)-1H-pirazol-4-il)pirimidin-2-ilamino)-N-((tetrahidro-2H-piran-4il)metil)benzamida; 3-ciclopentil-3-(4-(2-(4-((3-endo)-3-hidroxi-8-azabiciclo[3.2.1]octano-8-carbonil)fenilamino)pirimidin-4-il)-1Hpirazol-1-il)propanonitrilo; 3-ciclopentil-3-(4-(2-(4-(2-oxa-6-azatriciclo[3.3.1.1 (3,7)]dec-6-ilcarbonil)fenil)aminopirimidin-4-il)-1Hpirazol-1il)propanonitrilo; 4-(4-(1-(2-ciano-1-ciclopentiletil)-1H-pirazol-4-il)pirimidin-2-ilamino)-N-(cis-4-hidroxiciclohexil)-Nmetilbenzamida; 4-(4-(1-(2-ciano-1-ciclopentiletil)-1H-pirazol-4-il)pirimidin-2-ilamino)-N-metil-N-(tetrahidro-2H-piran-4il)benzamida; 3-ciclopentil-3-(4-(2-(4-(S*)-(4,4-dimetil-2-oxo-1-oxa-3,7-diazaspiro[4.4]nonano-7-carbonil)fenilamino)pirimidin4-il)-1H-pirazol-1-il)propanonitrilo; 3-ciclopentil-3-(4-(2-(4-(4,4-dimetil-1-oxa-7-azaspiro[4.4]nonano-7-carbonil)fenilamino)pirimidin-4-il)-1Hpirazol-1-il)propanonitrilo; 3-ciclopentil-3-(4-(2-(4-(4-metoxipiperidina-1-carbonil)fenilamino)pirimidin-4-il)-1H-pirazol-1-il)propanonitrilo; N-((3S)-1-(4-(4-(1-(2-ciano-1-ciclopentiletil)-1H-pirazol-4-il)pirimidin-2-ilamino)benzoil)pirrolidin-3-il)acetamida; 4-(4-(1-(2-ciano-1-ciclopentiletil)-1H-pirazol-4-il)pirimidin-2-ilamino)-N-(cis-4-hidroxiciclohexil)benzamida; 3-(4-(2-(4-(4-acetilpiperazina-1-carbonil)fenilamino)pirimidin-4-il)-1H-pirazol-1-il)-3-ciclopentilpropanonitrilo; (3S)-1-(4-(4-(1-(2-ciano-1-ciclopentiletil)-1H-pirazol-4-il)pirimidin-2-ilamino)benzoil)pirrolidina-3-carbonitrilo; 3-ciclopentil-3-(4-(2-(4-(3-metoxipirrolidina-1-carbonil)fenilamino)pirimidin-4-il)-1H-pirazol-1-il)propanonitrilo; 4-(4-(1-(2-ciano-1-ciclopentiletil)-1H-pirazol-4-il)pirimidin-2-ilamino)-N-(1-metilpiperidin-4-il)benzamida; 3-ciclopentil-3-(4-(2-(4-(3-oxo-2,8-diazaspiro[4.5]decano-8-carbonil)fenilamino)pirimidin-4-il)-1H-pirazol-1il)propanonitrilo; 3-ciclopentil-3-(4-(2-(4-(3-fluoropirrolidina-1-carbonil)fenilamino)pirimidin-4-il)-1H-pirazol-1-il)propanonitrilo; 3-ciclopentil-3-(4-(2-(4-(3-(dimetilamino)pirrolidina-1-carbonil)fenilamino)pirimidin-4-il)-1 H-pirazol-1il)propanonitrilo; etil 4-(4-(4-(1-(2-ciano-1-ciclopentiletil)-1H-pirazol-4-il)pirimidin-2-ilamino)benzamido)piperidina-1-carboxilato; 4-(4-(1-(2-ciano-1-ciclopentiletil)-1H-pirazol-4-il)pirimidin-2-ilamino)-N-(1-(piridin-2-il)pirrolidin-3-il)benzamida; 3-ciclopentil-3-(4-(2-(4-(3-(piridin-2-iloxi)pirrolidina-1-carbonil)fenilamino)pirimidin-4-il)-1H-pirazol-1il)propanonitrilo; 1-(4-(4-(1-(2-ciano-1-ciclopentiletil)-1H-pirazol-4-il)pinmidin-2-ilamino)benzoil)-N,N-dimetilpiperidina-4carboxamida; 4-(4-(1-(2-ciano-1-ciclopentiletil)-1H-pirazol-4-il)pirimidin-2-ilamino)-N-(1-(dimetilamino)-1-oxobutan-2il)benzamida; N-(3-(4-(1-(2-ciano-1-ciclopentiletil)-1H-pirazol-4-il)pirimidin-2-ilamino)fenil)-2-(4-metilpiperazin-1-il)acetamida; N-(3-(4-(1-(2-ciano-1-ciclopentiletil)-1H-pirazol-4-il)pirimidin-2-ilamino)fenil)-2-(3-hidroxipirrolidin-1il)acetamida; N-(3-(4-(1-(2-ciano-1-ciclopentiletil)-1H-pirazol-4-il)pirimidin-2-ilamino)fenil)-2-(3-oxopiperazin-1-il)acetamida; N-(3-(4-(1-(2-ciano-1-ciclopentiletil)-1H-pirazol-4-il)pirimidin-2-ilamino)fenil)-2-(4-hidroxipiperidin-1il)acetamida; N-(3-(4-(1-(2-ciano-1-ciclopentiletil)-1H-pirazol-4-il)pirimidin-2-ilamino)fenil)-2-(4-(2-hidroxietil)piperazin-1il)acetamida; N-(3-(4-(1-(2-ciano-1-ciclopentiletil)-1H-pirazol-4-il)pirimidin-2-ilamino)fenil)-2(ciclopropilmetilamino)acetamida; N-(3-(4-(1-(2-ciano-1-ciclopentiletil)-1H-pirazol-4-il)pirimidin-2-ilamino)fenil)-2-morfolinoacetamida; N-(3-(4-(1-(2-ciano-1-ciclopentiletil)-1H-pirazol-4-il)pirimidin-2-ilamino)fenil)-2-(etilamino)acetamida; 3-(cianometil)-3-(4-(2-(4-morfolinofenilamino)pirimidin-4-il)-1H-pirazol-1-il)ciclobutanocarbonitrilo; ácido 4-(4-(1-(3-(cianometil)-1-(etilsulfonil)azetidin-3-il)-1H-pirazol-4-il)pirimidin-2-ilamino)benzoico; ácido 4-(4-(1-(2-ciano-1-ciclopropiletil)-1H-pirazol-4-il)pirimidin-2-ilamino)benzoico; 3-ciclopropil-3-(4-(2-(4-(4-hidroxipiperidina-1-carbonil)fenilamino)pirimidin-4-il)-1H-pirazol-1-il)propanonitrilo; 3-ciclopropil-3-(4-(2-(4-((3-endo)-3-hidroxi-8-azabiciclo[3.2.1]octano-8-carbonil)fenilamino)pirimidin-4-il)-1Hpirazol-1-il)propanonitrilo; 3-ciclopropil-3-(4-(2-(4-(pirrolidina-1-carbonil)fenilamino)pirimidin-4-il)-1H-pirazol-1-il)propanonitrilo; 4-(4-(1-(2-ciano-1-ciclopropiletil)-1H-pirazol-4-il)pirimidin-2-ilamino)-N-(tetrahidro-2H-piran-4-il)benzamida; 2-(1-(etilsulfonil)-3-(4-(2-(4-(morfolin-4-carbonil)fenilamino)pirimidin-4-il)-1H-pirazol-1-il)azetidin-3il)acetonitrilo; 2-(1-(etilsulfonil)-3-(4-(2-(4-(4-hidroxipiperidina-1-carbonil)fenilamino)pirimidin-4-il)-1H-pirazol-1-il)azetidin-3il)acetonitrilo; 2-(1-(etilsulfonil)-3-(4-(2-(4-((3-endo)-3-hidroxi-8-azabiciclo[3.2.1]octano-8-carbonil)fenilamino)pirimidin-4-il)1H-pirazol-1-il)azetidin-3-il)acetonitrilo; 2-(1-(etilsulfonil)-3-(4-(2-(4-(pirrolidina-1-carbonil)fenilamino)pirimidin-4-il)-1H-pirazol-1-il)azetidin-3
    152
    il)acetonitrilo; 4-(4-(1-(3-(cianometil)-1-(etilsulfonil)azetidin-3-il)-1H-pirazol-4-il)pirimidin-2-ilamino)-N-(tetrahidro-2H-piran-4il)benzamida; 3-ciclopropil-3-(4-(2-(4-(morfolin-4-carbonil)fenilamino)pirimidin-4-il)-1H-pirazol-1-il)propanonitrilo; 3-(4-(2-(4-(azetidina-1-carbonil)fenilamino)pirimidin-4-il)-1H-pirazol-1-il)-3-ciclopropilpropanonitrilo; 3-ciclopropil-3-(4-(2-(4-(2-oxa-6-azatriciclo[3.3.1.1(3,7)]dec-6-ilcarbonil)fenil)aminopirimidin-4-il)-1H-pirazol-1il)propanonitrilo; 3-ciclopropil-3-(4-(2-(4-(4-metoxipiperidina-1-carbonil)fenilamino)pirimidin-4-il)-1H-pirazol-1-il)propanonitrilo; (3R)-1-(4-(4-(1-(2-ciano-1-ciclopropiletil)-1H-pirazol-4-il)pirimidin-2-ilamino)benzoil)pirrolidina-3-carbonitrilo; 3-ciclopropil-3-(4-(2-(4-(3-metoxipirrolidina-1-carbonil)fenilamino)pirimidin-4-il)-1H-pirazol-1-il)propanonitrilo; 3-ciclopropil-3-(4-(2-(4-(3-hidroxipirrolidina-1-carbonil)fenilamino)pirimidin-4-il)-1H-pirazol-1-il)propanonitrilo; 3-ciclopropil-3-(4-(2-(4-(4-metilpiperazina-1-carbonil)fenilamino)pirimidin-4-il)-1H-pirazol-1-il)propanonitrilo; N-((3R)-1-(4-(4-(1-(2-ciano-1-ciclopropiletil)-1H-pirazol-4-il)pirimidin-2-ilamino)benzoil)pirrolidin-3-il)acetamida; 3-(4-(2-(4-(4-acetilpiperazina-1-carbonil)fenilamino)pirimidin-4-il)-1H-pirazol-1-il)-3-ciclopropilpropanonitrilo; 3-ciclopropil-3-(4-(2-(4-(3-(dimetilamino)pirrolidina-1-carbonil)fenilamino)pirimidin-4-il)-1H-pirazol-1il)propanonitrilo; 3-ciclopropil-3-(4-(2-(4-(3-fluoropirrolidina-1-carbonil)fenilamino)pirimidin-4-il)-1H-pirazol-1-il)propanonitrilo; etil 4-(4-(4-(1-(2-ciano-1-ciclopropiletil)-1H-pirazol-4-il)pirimidin-2-ilamino)benzoil)aminopiperidina-1carboxilato; 2-(3-(4-(2-(4-(azetidina-1-carbonil)fenilamino)pirimidin-4-il)-1H-pirazol-1-il)-1-(etilsulfonil)azetidin-3il)acetonitrilo; 1-(etilsulfonil)-3-(4-(2-(4-(2-oxa-6-azatriciclo[3.3.1.1(3,7)]dec-6-ilcarbonil)fenil)aminopirimidin-4-il)-1H-pirazol1-il)azetidin-3-ilacetonitrilo; (1-(etilsulfonil)-3-4-(2-(4-((4-metoxipiperidin-1-il)carbonil)fenilamino)pirimidin-4-il)-1H-pirazol-1-ilazetidin-3il)acetonitrilo; 1-(4-(4-(1-(3-(cianometil)-1-(etilsulfonil)azetidin-3-il)-1H-pirazol-4-il)pirimidin-2-ilamino)benzoil)pirrolidina-3carbonitrilo; 2-(1-(etilsulfonil)-3-(4-(2-(4-(3-metoxipirrolidina-1-carbonil)fenilamino)pirimidin-4-il)-1H-pirazol-1-il)azetidin-3il)acetonitrilo; 2-(1-(etilsulfonil)-3-(4-(2-(4-(3-hidroxipirrolidina-1-carbonil)fenilamino)pirimidin-4-il)-1H-pirazol-1-il)azetidin-3 il)acetonitrilo; 2-(1-(etilsulfonil)-3-(4-(2-(4-(4-metilpiperazina-l-carbonil)fenilamino)pirimidin-4-il)-1H-pirazol-1-il)azetidin-3 il)acetonitrilo; N-(1-(4-(4-(1-(3-(cianometil)-1-(etilsulfonil)azetidin-3-il)-1H-pirazol-4-il)pirimidin-2-ilamino)benzoil)pirrolidin-3il)acetamida; 2-(3-(4-(2-(4-(4-acetilpiperazina-1-carbonil)fenilamino)pirimidin-4-il)-1H-pirazol-1-il)-1-(etilsulfonil)azetidin-3il)acetonitrilo; 2-(3-(4-(2-(4-(3-(dimetilamino)pirrolidina-1-carbonil)fenilamino)pirimidin-4-il)-1H-pirazol-1-il)-1(etilsulfonil)azetidin-3-il)acetonitrilo; 2-(1-(etilsulfonil)-3-(4-(2-(4-(3-fluoropirrolidina-1-carbonil)fenilamino)pirimidin-4-il)-1H-pirazol-1-il)azetidin-3il)acetonitrilo; etil 4-(4-(4-(1-(3-(cianometil)-1-(etilsulfonil)azetidin-3-il)-1H-pirazol-4-il)pirimidin-2ilamino)benzamido)piperidina-1-carboxilato; ácido 4-(4-(1-(3-ciano-1-(cianometil)ciclobutil)-1H-pirazol-4-il)pirimidin-2-ilamino)benzoico; ácido 4-(4-(1-(2-ciano-1-ciclopentiletil)-1H-pirazol-4-il)-5-metoxipirimidin-2-ilamino)benzoico; 3-(cianometil)-3-(4-(2-(4-(morfolin-4-carbonil)fenilamino)pirimidin-4-il)-1H-pirazol-1-il)ciclobutanocarbonitrilo; 3-(cianometil)-3-(4-(2-(4-(pirrolidina-1-carbonil)fenilamino)pirimidin-4-il)-1H-pirazol-1-il)ciclobutanocarbonitrilo; 4-(4-(1-(3-ciano-1-(cianometil)ciclobutil)-1H-pirazol-4-il)pirimidin-2-ilamino)-N-(tetrahidro-2H-piran-4il)benzamida; 3-(cianometil)-3-(4-(2-(4-(3-hidroxipirrolidina-1-carbonil)fenilamino)pirimidin-4-il)-1 H-pirazol-1il)ciclobutanocarbonitrilo; 4-(4-(1-(3-ciano-1-(cianometil)ciclobutil)-1H-pirazol-4-il)pirimidin-2-ilamino)-N-((5-metilisoxazol-3il)metil)benzamida; 3-(4-(2-(4-(azetidina-1-carbonil)fenilamino)pirimidin-4-il)-1H-pirazol-1-il)-3-(cianometil)ciclobutanocarbonitrilo; 3-(cianometil)-3-(4-(2-(4-(4-metilpiperazina-1-carbonil)fenilamino)pirimidin-4-il)-1H-pirazol-1il)ciclobutanocarbonitrilo; 3-(cianometil)-3-(4-(2-(4-(3-fluoropirrolidina-1-carbonil)fenilamino)pirimidin-4-il)-1H-pirazol-1il)ciclobutanocarbonitrilo; 3-(cianometil)-3-(4-(2-(4-(4-metoxipiperidina-1-carbonil)fenilamino)pirimidin-4-il)-1H-pirazol-1il)ciclobutanocarbonitrilo; 3-(cianometil)-3-(4-(2-(4-(3-metoxipirrolidina-1-carbonil)fenilamino)pirimidin-4-il)-1H-pirazol-1il)ciclobutanocarbonitrilo; 1-(4-(4-(1-(3-ciano-1-(cianometil)ciclobutil)-1H-pirazol-4-il)pirimidin-2-ilamino)benzoil)pirrolidina-3-carbonitrilo; 3-(4-(2-(4-(4-acetilpiperazina-1-carbonil)fenilamino)pirimidin-4-il)-1H-pirazol-1-il)-3(cianometil)ciclobutanocarbonitrilo;
    153
    imagen8
    imagen9
    imagen10
    imagen11
ES08848610.5T 2007-11-16 2008-11-13 4-pirazolil-N-arilpirimidin-2-aminas y 4-pirazolil-N-heteroarilpirimidin-2-aminas como inhibidores de quinasas Janus Active ES2569528T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US98860607P 2007-11-16 2007-11-16
US988606P 2007-11-16
PCT/US2008/083319 WO2009064835A1 (en) 2007-11-16 2008-11-13 4-pyrazolyl-n-arylpyrimidin-2-amines and 4-pyrazolyl-n-heteroarylpyrimidin-2-amines as janus kinase inhibitors

Publications (1)

Publication Number Publication Date
ES2569528T3 true ES2569528T3 (es) 2016-05-11

Family

ID=40380038

Family Applications (1)

Application Number Title Priority Date Filing Date
ES08848610.5T Active ES2569528T3 (es) 2007-11-16 2008-11-13 4-pirazolil-N-arilpirimidin-2-aminas y 4-pirazolil-N-heteroarilpirimidin-2-aminas como inhibidores de quinasas Janus

Country Status (21)

Country Link
US (1) US8309718B2 (es)
EP (1) EP2220068B1 (es)
JP (1) JP5480813B2 (es)
KR (1) KR101580482B1 (es)
CN (1) CN101910152B (es)
AU (1) AU2008321046B2 (es)
BR (1) BRPI0820544A2 (es)
CA (1) CA2704599C (es)
CO (1) CO6280420A2 (es)
CR (1) CR11430A (es)
EA (1) EA020777B1 (es)
EC (1) ECSP10010263A (es)
ES (1) ES2569528T3 (es)
HK (1) HK1147476A1 (es)
IL (1) IL205571A (es)
MX (1) MX2010005300A (es)
MY (1) MY152948A (es)
NZ (1) NZ585139A (es)
UA (1) UA104849C2 (es)
WO (1) WO2009064835A1 (es)
ZA (1) ZA201004055B (es)

Families Citing this family (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060106020A1 (en) * 2004-04-28 2006-05-18 Rodgers James D Tetracyclic inhibitors of Janus kinases
UA98449C2 (en) 2005-12-13 2012-05-25 Инсайт Корпорейшин Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
US8513270B2 (en) * 2006-12-22 2013-08-20 Incyte Corporation Substituted heterocycles as Janus kinase inhibitors
RS53245B2 (sr) 2007-06-13 2022-10-31 Incyte Holdings Corp Soli inhibitora janus kinaze (r)-3-(4-(7h-pirolo(2,3-d) pirimidin-4-il)-1h-pirazol-1-il)-3-ciklopentilpropan-nitrila
CL2008001709A1 (es) 2007-06-13 2008-11-03 Incyte Corp Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
FR2938537B1 (fr) 2008-11-14 2012-10-26 Sanofi Aventis Derives de carbamates d'alkyl-heterocycles, leur preparation et leur application en therapeutique.
JOP20190230A1 (ar) 2009-01-15 2017-06-16 Incyte Corp طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به
BRPI1012159B1 (pt) 2009-05-22 2022-01-25 Incyte Holdings Corporation Compostos derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo[2,3-d] pirimidinas e pirrol-3-il-pirrolo[2,3-d] pirimidinas como inibidores de janus cinase, composições farmacêuticas compreendendo os referidos compostos e usos dos mesmos
LT2432472T (lt) 2009-05-22 2020-02-10 Incyte Holdings Corporation 3-[4-(7h-pirolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]oktan- arba heptan-nitrilas, kaip jak inhibitoriai
AR078012A1 (es) 2009-09-01 2011-10-05 Incyte Corp Derivados heterociclicos de las pirazol-4-il- pirrolo (2,3-d) pirimidinas como inhibidores de la quinasa janus
US20110207736A1 (en) * 2009-12-23 2011-08-25 Gatekeeper Pharmaceuticals, Inc. Compounds that modulate egfr activity and methods for treating or preventing conditions therewith
EP2534258B1 (en) * 2010-02-10 2017-09-20 Genon Biotechnologies OY Dual activity kinase domains and uses thereof
CA2790070C (en) * 2010-02-18 2018-03-06 Incyte Corporation Cyclobutane and methylcyclobutane derivatives as janus kinase inhibitors
AU2011224484A1 (en) 2010-03-10 2012-09-27 Incyte Holdings Corporation Piperidin-4-yl azetidine derivatives as JAK1 inhibitors
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
CN103002875B (zh) 2010-05-21 2016-05-04 因塞特控股公司 Jak抑制剂的局部用制剂
US8354420B2 (en) 2010-06-04 2013-01-15 Genentech, Inc. Aminopyrimidine derivatives as LRRK2 inhibitors
CA2815330A1 (en) * 2010-11-09 2012-05-18 Cellzome Limited Pyridine compounds and aza analogues thereof as tyk2 inhibitors
PL3124483T3 (pl) 2010-11-10 2020-03-31 Genentech, Inc. Pirazolowo-aminopirymidynowe pochodne jako modulatory LRRK2
ES2536415T3 (es) 2010-11-19 2015-05-25 Incyte Corporation Pirrolopiridinas y pirrolopirimidinas sustituidas heterocíclicas como inhibidores de JAK
PE20140146A1 (es) 2010-11-19 2014-02-06 Incyte Corp Derivados de pirrolopiridina y pirrolopirimidina sustituidos con ciclobutilo como inhibidores de jak
GB201020179D0 (en) 2010-11-29 2011-01-12 Astex Therapeutics Ltd New compounds
CN103732226B (zh) 2011-02-18 2016-01-06 诺瓦提斯药物公司 mTOR/JAK抑制剂组合疗法
JP5976778B2 (ja) * 2011-04-11 2016-08-24 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ キナーゼ阻害剤としてのピラゾリル−ピリミジン誘導体
AR086983A1 (es) 2011-06-20 2014-02-05 Incyte Corp Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak
EP2741747A1 (en) 2011-08-10 2014-06-18 Novartis Pharma AG JAK P13K/mTOR COMBINATION THERAPY
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
AU2012312303B2 (en) * 2011-09-22 2016-09-15 Merck Sharp & Dohme Corp. Cyanomethylpyrazole carboxamides as janus kinase inhibitors
GB201118656D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118654D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118652D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118675D0 (en) 2011-10-28 2011-12-14 Astex Therapeutics Ltd New compounds
CN103102359B (zh) * 2011-11-15 2016-11-09 江苏先声药业有限公司 嘧啶类化合物及其应用
CA3131037A1 (en) 2011-11-30 2013-06-06 Emory University Antiviral jak inhibitors useful in treating or preventing retroviral and other viral infections
WO2013173720A1 (en) 2012-05-18 2013-11-21 Incyte Corporation Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
GB201209613D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
GB201209609D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
CA2880896C (en) 2012-06-26 2021-11-16 Del Mar Pharmaceuticals Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof
US8809359B2 (en) * 2012-06-29 2014-08-19 Ym Biosciences Australia Pty Ltd Phenyl amino pyrimidine bicyclic compounds and uses thereof
US9546152B2 (en) 2012-10-23 2017-01-17 Merck Sharp & Dohme Corp. 2-pyridyloxy-3-substituted-4-nitrile orexin receptor antagonists
MX2015005428A (es) 2012-11-01 2015-07-21 Incyte Corp Derivados triciclicos fusionados de tiofeno como inhibidores de la cinasa janus (jak).
KR20150105302A (ko) 2012-11-05 2015-09-16 난트 홀딩스 아이피, 엘엘씨 헤지 호그 신호 경로의 억제제로서 환상 술폰아미드 함유 유도체
MY191357A (en) 2012-11-15 2022-06-19 Incyte Holdings Corp Sustained-release dosage forms of ruxolitinib
WO2014075318A1 (zh) * 2012-11-19 2014-05-22 江苏先声药业有限公司 嘧啶类化合物及其应用
SG10201600149VA (en) 2012-11-21 2016-02-26 Ptc Therapeutics Inc Substituted reverse pyrimidine bmi-1 inhibitors
UA120162C2 (uk) * 2013-03-06 2019-10-25 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки при отриманні інгібітора jak
WO2014146249A1 (en) * 2013-03-19 2014-09-25 Merck Sharp & Dohme Corp. Geminally substituted cyanoethylpyrazolo pyridones as janus kinase inhibitors
GB201307577D0 (en) 2013-04-26 2013-06-12 Astex Therapeutics Ltd New compounds
TWI719401B (zh) * 2013-05-17 2021-02-21 美商英塞特公司 作為jak抑制劑之聯吡唑衍生物
WO2014196793A1 (en) * 2013-06-05 2014-12-11 C&C Research Laboratories Heterocyclic derivatives and use thereof
PT3030227T (pt) 2013-08-07 2020-06-25 Incyte Corp Formas de dosagem de libertação prolongada para um inibidor de jak1
EP3039015B1 (en) 2013-08-30 2019-10-30 PTC Therapeutics, Inc. Substituted pyrimidine bmi-1 inhibitors
WO2015067630A1 (de) 2013-11-08 2015-05-14 Bayer Pharma Aktiengesellschaft Substituierte uracile und ihre verwendung
US10584115B2 (en) 2013-11-21 2020-03-10 Ptc Therapeutics, Inc. Substituted pyridine and pyrazine BMI-1 inhibitors
CN104860941B (zh) * 2014-02-25 2017-03-22 上海海雁医药科技有限公司 2,4‑二取代苯‑1,5‑二胺衍生物及其应用以及由其制备的药物组合物和药用组合物
PL3122358T3 (pl) 2014-03-26 2021-06-14 Astex Therapeutics Ltd. Połączenia inhibitorów fgfr i cmet w leczeniu nowotworu
JO3512B1 (ar) 2014-03-26 2020-07-05 Astex Therapeutics Ltd مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
RU2715893C2 (ru) 2014-03-26 2020-03-04 Астекс Терапьютикс Лтд Комбинации ингибитора fgfr и ингибитора igf1r
WO2015168246A1 (en) 2014-04-30 2015-11-05 Incyte Corporation Processes of preparing a jak1 inhibitor and new forms thereto
US9498467B2 (en) 2014-05-30 2016-11-22 Incyte Corporation Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
WO2016105525A2 (en) * 2014-12-23 2016-06-30 Dana-Farber Cancer Institute, Inc. Novel pyrimidines as egfr inhibitors and methods of treating disorders
JOP20200201A1 (ar) 2015-02-10 2017-06-16 Astex Therapeutics Ltd تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
US10561646B2 (en) 2015-07-24 2020-02-18 Shanghai Haiyan Pharmaceutical Technology Co. Ltd. EGFR inhibitor and pharmaceutically acceptable salt and polymorph thereof, and use thereof
HUE057090T2 (hu) 2015-09-23 2022-04-28 Janssen Pharmaceutica Nv BI-heteroaril-szubsztituált 1,4-benzodiazepinek és alkalmazásuk rák kezelésében
BR112018005637B1 (pt) 2015-09-23 2023-11-28 Janssen Pharmaceutica Nv Compostos derivados de quinoxalina, quinolina e quinazolinona,composições farmacêuticas que os compreende, e uso dos referidos compostos
WO2018098250A1 (en) * 2016-11-22 2018-05-31 Development Center For Biotechnology Hetroarylamine compounds for modulating the hedgehog pathway and preparing method and uses thereof
WO2019079469A1 (en) 2017-10-18 2019-04-25 Incyte Corporation CONDENSED IMIDAZOLE DERIVATIVES SUBSTITUTED WITH HYDROXY TERTIARY GROUPS AS INHIBITORS OF PI3K-GAMMA
WO2019113487A1 (en) 2017-12-08 2019-06-13 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
KR20200129099A (ko) 2018-01-30 2020-11-17 인사이트 코포레이션 (1-(3-플루오로-2-(트리플루오로메틸)이소니코티닐)피페리딘-4-온)의 제조 방법
IL276725B2 (en) 2018-02-16 2024-09-01 Incyte Corp JAK1 pathway inhibitors for the treatment of cytokine-related disorders
JP7565798B2 (ja) 2018-03-30 2024-10-11 インサイト・コーポレイション 炎症性皮膚疾患のバイオマーカー
CN112423759A (zh) 2018-03-30 2021-02-26 因赛特公司 使用jak抑制剂治疗化脓性汗腺炎
SG11202010092XA (en) 2018-04-13 2020-11-27 Incyte Corp Biomarkers for graft-versus-host disease
BR112021002630A2 (pt) 2018-08-17 2021-05-11 Ptc Therapeutics, Inc. método para tratar câncer pancreático
JP2021535182A (ja) 2018-09-05 2021-12-16 インサイト・コーポレイションIncyte Corporation ホスホイノシチド３−キナーゼ（ｐｉ３ｋ）阻害剤の結晶形態
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
WO2020087024A1 (en) * 2018-10-26 2020-04-30 Arrien Pharmaceuticals Llc Pyrazolyl compounds and methods of use thereof
JP7431845B2 (ja) 2018-10-31 2024-02-15 インサイト・コーポレイション 血液疾患の治療のための併用療法
WO2020118683A1 (en) * 2018-12-14 2020-06-18 Lynk Pharmaceuticals Co. Ltd. Benzamides of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof
WO2020168197A1 (en) 2019-02-15 2020-08-20 Incyte Corporation Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors
US11472791B2 (en) 2019-03-05 2022-10-18 Incyte Corporation Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors
WO2020205560A1 (en) 2019-03-29 2020-10-08 Incyte Corporation Sulfonylamide compounds as cdk2 inhibitors
AU2020257301A1 (en) 2019-04-18 2021-11-11 The Johns Hopkins University Substituted 2-amino-pyrazolyl-(1,2,4)triazolo(1,5a) pyridine derivatives and use thereof
WO2020223469A1 (en) 2019-05-01 2020-11-05 Incyte Corporation N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer
US11447494B2 (en) 2019-05-01 2022-09-20 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
US20220298140A1 (en) * 2019-06-28 2022-09-22 Chengdu Zenitar Biomedical Technology Co., Ltd. 2,4-disubstituted pyrimidine derivative, preparation method therefor and use thereof
CN112142731B (zh) * 2019-06-28 2022-07-22 成都赜灵生物医药科技有限公司 一种2，4-二取代嘧啶衍生物及其制备方法和用途
WO2021030537A1 (en) 2019-08-14 2021-02-18 Incyte Corporation Imidazolyl pyrimidinylamine compounds as cdk2 inhibitors
PE20221905A1 (es) 2019-10-11 2022-12-23 Incyte Corp Aminas biciclicas como inhibidoras de la cdk2
WO2021102258A1 (en) 2019-11-22 2021-05-27 Incyte Corporation Combination therapy comprising an alk2 inhibitor and a jak2 inhibitor
US20240254103A9 (en) * 2020-03-23 2024-08-01 Whan In Pharmaceutical Co., Ltd. Novel pyrimidine derivative, and composition for preventing or treating neurodegenerative diseases and cancer, comprising same
US11685731B2 (en) 2020-06-02 2023-06-27 Incyte Corporation Processes of preparing a JAK1 inhibitor
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
PE20231743A1 (es) 2020-08-18 2023-10-31 Incyte Corp Proceso e intermediarios para preparar un inhibidor de jak
TW202212341A (zh) 2020-08-18 2022-04-01 美商英塞特公司 製備ｊａｋ１抑制劑之方法及中間體
CN114181199B (zh) * 2020-09-15 2023-09-26 成都赜灵生物医药科技有限公司 2，4-二取代嘧啶衍生物及其制备方法和用途
EP4259131A1 (en) 2020-12-08 2023-10-18 Incyte Corporation Jak1 pathway inhibitors for the treatment of vitiligo
CN114874189B (zh) * 2021-02-05 2023-09-29 深圳市塔吉瑞生物医药有限公司 取代的杂芳基衍生物及其组合物及用途
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
WO2023288197A1 (en) 2021-07-12 2023-01-19 Incyte Corporation Process and intermediates for preparing baricitinib
CN118159528A (zh) * 2021-10-06 2024-06-07 爱瑞制药公司 抑制Janus激酶的吡唑化合物及其用途
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors
WO2024041397A1 (en) * 2022-08-22 2024-02-29 Hangzhou Highlightll Pharmaceutical Co., Ltd Jak1/jak2/tyk2 inhibitors for topical treatment of dermatological diseases
CN115594664B (zh) * 2022-11-25 2023-02-24 英矽智能科技(上海)有限公司 一类螺环衍生物作为kif18a抑制剂

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
BR9910864A (pt) 1998-06-04 2002-02-05 Abbott Lab Compostos anti-inflamatórios para inibição de aderência celular
PA8474101A1 (es) 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
BR9912938B1 (pt) 1998-08-11 2011-06-28 derivados de isoquinolina, composição que os compreende, processo para preparação e uso dos mesmos.
US6133031A (en) 1999-08-19 2000-10-17 Isis Pharmaceuticals Inc. Antisense inhibition of focal adhesion kinase expression
GB9905075D0 (en) 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
KR100477818B1 (ko) 1999-12-10 2005-03-22 화이자 프로덕츠 인코포레이티드 피롤로[2,3-ｄ] 피리미딘 화합물
OA12514A (en) 1999-12-24 2006-05-29 Aventis Pharma Ltd Azaindoles.
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
CZ303572B6 (cs) 2000-06-28 2012-12-12 Smithkline Beecham P. L. C. Jemne rozmelnený prostredek a zpusob jeho prípravy
AU2002228783A1 (en) * 2000-12-05 2002-06-18 Vertex Pharmaceuticals Incorporated Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
CA2446864C (en) * 2001-05-16 2011-02-15 Vertex Pharmaceuticals Incorporated Inhibitors of src and other protein kinases
CN100391958C (zh) 2001-09-19 2008-06-04 安万特医药股份有限公司 化合物
CA2462657C (en) 2001-10-30 2011-04-26 Novartis Ag Staurosporine derivatives as inhibitors of flt3 receptor tyrosine kinase activity
AR037647A1 (es) 2002-05-29 2004-12-01 Novartis Ag Derivados de diarilurea utiles para el tratamiento de enfermedades dependientes de la cinasa de proteina
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
GB0215844D0 (en) * 2002-07-09 2002-08-14 Novartis Ag Organic compounds
CL2003002353A1 (es) 2002-11-15 2005-02-04 Vertex Pharma Compuestos derivados de diaminotriazoles, inhibidores d ela proteina quinasa; composicion farmaceutica; procedimiento de preparacion; y su uso del compuesto en el tratamiento de enfermedades de desordenes alergicos, proliferacion, autoinmunes, condic
UA80767C2 (en) 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
CA2515132C (en) 2003-02-07 2012-01-03 Vertex Pharmaceuticals Incorporated Heteroaryl substituted pyrroles useful as inhibitors of protein kinases
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
SE0301373D0 (sv) 2003-05-09 2003-05-09 Astrazeneca Ab Novel compounds
SE0301372D0 (sv) 2003-05-09 2003-05-09 Astrazeneca Ab Novel compounds
AR045944A1 (es) 2003-09-24 2005-11-16 Novartis Ag Derivados de isoquinolina 1.4-disustituidas
MY141220A (en) 2003-11-17 2010-03-31 Astrazeneca Ab Pyrazole derivatives as inhibitors of receptor tyrosine kinases
US20060106020A1 (en) 2004-04-28 2006-05-18 Rodgers James D Tetracyclic inhibitors of Janus kinases
CA2586375A1 (en) * 2004-11-04 2006-05-18 Juan-Miguel Jimenez Pyrazolo[1,5-a]pyrimidines useful as inhibitors of protein kinases
AR054416A1 (es) 2004-12-22 2007-06-27 Incyte Corp Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.
CA2621261C (en) 2005-09-22 2014-05-20 Incyte Corporation Azepine inhibitors of janus kinases
EP2388259A1 (en) 2005-10-28 2011-11-23 AstraZeneca AB 4- (3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer
UA98449C2 (en) 2005-12-13 2012-05-25 Инсайт Корпорейшин Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
AU2007215247B2 (en) * 2006-02-10 2012-12-13 Transtech Pharma, Llc Benzazole derivatives, compositions, and methods of use as Aurora kinase inhibitors
WO2007105058A2 (en) * 2006-03-16 2007-09-20 Pfizer Products Inc. Pyrazole compounds
WO2007129195A2 (en) * 2006-05-04 2007-11-15 Pfizer Products Inc. 4-pyrimidine-5-amino-pyrazole compounds
US8513270B2 (en) 2006-12-22 2013-08-20 Incyte Corporation Substituted heterocycles as Janus kinase inhibitors
RS53245B2 (sr) 2007-06-13 2022-10-31 Incyte Holdings Corp Soli inhibitora janus kinaze (r)-3-(4-(7h-pirolo(2,3-d) pirimidin-4-il)-1h-pirazol-1-il)-3-ciklopentilpropan-nitrila
CL2008001709A1 (es) 2007-06-13 2008-11-03 Incyte Corp Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
JP5275371B2 (ja) 2008-03-11 2013-08-28 インサイト・コーポレイション Ｊａｋ阻害剤としてのアゼチジン誘導体およびシクロブタン誘導体
CL2009001884A1 (es) 2008-10-02 2010-05-14 Incyte Holdings Corp Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
JOP20190230A1 (ar) 2009-01-15 2017-06-16 Incyte Corp طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به
BRPI1012159B1 (pt) 2009-05-22 2022-01-25 Incyte Holdings Corporation Compostos derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo[2,3-d] pirimidinas e pirrol-3-il-pirrolo[2,3-d] pirimidinas como inibidores de janus cinase, composições farmacêuticas compreendendo os referidos compostos e usos dos mesmos
LT2432472T (lt) 2009-05-22 2020-02-10 Incyte Holdings Corporation 3-[4-(7h-pirolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]oktan- arba heptan-nitrilas, kaip jak inhibitoriai

Also Published As

Publication number Publication date
HK1147476A1 (zh) 2011-08-12
IL205571A0 (en) 2010-12-30
WO2009064835A1 (en) 2009-05-22
CN101910152A (zh) 2010-12-08
CA2704599A1 (en) 2009-05-22
CR11430A (es) 2010-07-01
NZ585139A (en) 2012-05-25
US20090318405A1 (en) 2009-12-24
CA2704599C (en) 2015-05-12
EA201070618A1 (ru) 2010-12-30
UA104849C2 (uk) 2014-03-25
KR20100095582A (ko) 2010-08-31
AU2008321046A1 (en) 2009-05-22
KR101580482B1 (ko) 2015-12-28
EP2220068A1 (en) 2010-08-25
MX2010005300A (es) 2010-06-25
EP2220068B1 (en) 2016-01-27
ZA201004055B (en) 2012-09-26
BRPI0820544A2 (pt) 2015-06-16
US8309718B2 (en) 2012-11-13
CO6280420A2 (es) 2011-05-20
AU2008321046B2 (en) 2013-10-24
ECSP10010263A (es) 2010-07-30
JP5480813B2 (ja) 2014-04-23
EA020777B1 (ru) 2015-01-30
JP2011503194A (ja) 2011-01-27
CN101910152B (zh) 2014-08-06
MY152948A (en) 2014-12-15
IL205571A (en) 2015-09-24

Similar Documents

Publication Publication Date Title
ES2569528T3 (es) 4-pirazolil-N-arilpirimidin-2-aminas y 4-pirazolil-N-heteroarilpirimidin-2-aminas como inhibidores de quinasas Janus
HRP20192033T1 (hr) Ciklopropilamini kao lsd1 inhibitori
ES2554228T3 (es) Ciclopenta[d]pirimidinas hidroxiladas como inhibidores de la proteína quinasa AKT
JP2017510555A5 (es)
RU2498983C2 (ru) Соединения фениламинопиримидина и их применения
HRP20180037T1 (hr) Heterociklični spoj koji sadrži dušik ili njegovu sol
HRP20161171T1 (hr) AMIDINSKI SUPSTITUIRANI β-LAKTAMSKI SPOJEVI, NJIHOVA PRIPRAVA I UPOTREBA KAO ANTIBAKTERIJSKIH SREDSTAVA
RS52210B (en) CYCLOPENT [D] PYRIMIDINS AS PROTEIN KINASE ACTION INHIBITORS
RU2009126624A (ru) Производные 2-(пиперидин-4-ил)-4-фенокси-или фенилаинопиримидина в качестве ненуклеозидных ингибитров обратной транскриптазы
JP2014511869A5 (es)
AR048691A1 (es) Compuestos con estructura de alquino con accion antagonista de mch y medicamentos que contienen estos compuestos
HRP20140252T1 (hr) Derivati imidazola kao inhibitori kazeinske kinaze
HRP20120240T1 (hr) Piridil piperidin antagonisti receptora za oreksin
JP2019505541A5 (es)
NZ594597A (en) Substituted piperidines as ccr3 antagonists
AR073920A1 (es) Derivados urea de nortropanos sustituidos, medicamentos que contienen dichos compuestos , su uso en el tratamiento de enfermedades mediadas por la inhibicion de la enzima 11beta-hidroxiesteroide deshidrogenasa y proceso para su preparacion.
JP2013510876A5 (es)
HRP20201430T1 (hr) Spojevi 6-heterociklil-4-morfolin-4-ilpiridin-2-ona korisni za liječenje karcinoma i dijabetesa
HRP20130174T1 (hr) Derivati pirimidina za lijeäśenje astme, kopb, alergijskog rinitisa, alergijskog konjuktivitisa, atopijskog dermatitisa, karcinoma, hepatitisa b, hepatitisa c, hiv, hpv, bakterijskih infekcija i dermatoze
RU2009148673A (ru) Производные пиразинона и их применение для лечения легочных заболеваний
JP2008513500A5 (es)
HRP20171554T1 (hr) Novi imidazol amini kao modulatori aktivnosti kinaze
RU2008120619A (ru) (гетеро)арилы, обладающие антагонистической активностью по отношению к меланинконцентрирующему гормону
AR045587A1 (es) Derivados de acil piperazinas sustituidas, proceso de obtencion, uso y composiciones farmaceuticas que las contienen
RU2005132616A (ru) Производные 2-фенокси и 2-фенилсульфонамида с ссr3 антагонистической активностью для лечения астмы и других воспалительных или иммунологических заболеваний